Afatinib for glioblastoma – pro
Reardon found that Afatinib has a manageable safety profile but limited single-agent activity in unselected recurrent GBM patients. Abastract by Esuisenstadt says: “Afatinib has limited single-agent activity in recurrent GBM; however, potential activity in biomarker-selected pts warrants further evaluation.” Clearly more investigt=ation si warranted before it is routinely used.
Reardon DA et al, Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. Neuro Oncol. 2015 Mar;17(3):430-9
A phase II study of daily afatinib (BIBW 2992) with or without temozolomide (21/28 days) in the treatment of patients with recurrent glioblastoma.